Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see ECOR at $10 following ARDS EUA And OTC approval.
$ECOR - No “Off Label” Use in OTC market - restrictions off -Gammacore will sell. (See $LAKE)
$ECOR- Imagine an OTC device that treats COVID! Will be more popular than a mask.
$ECOR OTC approval will attract $AMZN - will hear Ring Doorbell going off.
$ECOR OTC approval will be attractive to $JNJ and $BHC
- 2 Pharma companies with large OTC sales force To sell Gammacore.
$ECOR safety allows OTC Use -Will be a huge boost to sales revenues. Company will still sell monthly treatment - no such thing as off label once OTC - big # of indications.
ECOR Zooming in Premarket - 98762784301
ECOR Premarket Zoom tomorrow "Zooming with LD Micro
Format: corporate presentation followed by 1x1 virtual investor meetings
Date: Tuesday, July 21
Time: 8:00am – 8:40am PT"
"In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector."
$ECOR
Works in Migraine, Cluster Headache, Crohns Disease, Arthritis, Asthma,and in at least 2 Patients with COVID related nonasthmatic dyspnea (trouble breathing) - it works- I got that message directly from Dr Kevin Tracey -Feinstein Institute CEO @ Northwell Health. The only barrier to $10 is in repeated demonstration That it works. More tomorrow.
ECOR ARDS EUA on - “Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis” in “Noninvasive transcutaneous vagus nerve stimulation decreases whole blood culture-derived cytokines and chemokines: a randomized, blinded, healthy control pilot trial”
https://scholar.google.com/scholar?as_ylo=2016&q=vagal+stimulation++cytokines&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DvNBpAOLJR9AJ
ECOR “The role of the vagus nerve in anti-inflammatory reflex has opened the opportunity for the scientists to study ANS mediated anti-inflammatory responses. Apart from the immediate significance of the term anti-inflammatory reflex, the biological and clinical consequences of this immune system hyperactivity are by far less known, making it worthwhile to be overviewed. I would like to add further that excessive uncontrolled inflammatory response results in cytokine storms syndrome which is nothing but fatal hyper-cytokinemia associated with multiorgan failure”
ECOR -COVID19-“Vagus Nerve Stimulation could also Alleviate Respiratory Infections as Part of its Anti-inflammatory Property” https://ijcep.phcog.interactivedns.com/index.php/ijcep/article/view/525
ECOR for Obesity “Vagal N Stimulation with appropriate parameters reduced food intake and body weight by delaying gastric emptying mediated via the enhancement of vagal activity” https://scholar.google.com/scholar?as_ylo=2020&q=vagal+nerve+stimulation+and+weight+loss&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DaOx1mSJoBQ8J
Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib https://www.biospace.com/article/releases/bergenbio-announces-first-patient-dosed-in-recurrent-glioblastoma-investigator-sponsored-phase-i-ii-study-assessing-selective-axl-inhibitor-bemcentinib/
BABA -“Alibaba-backed Ant Group plans (Huge) IPOs in Hong Kong, Shanghai” https://www.google.com/amp/s/m.businesstoday.in/lite/story/alibaba-backed-ant-group-plans-ipos-in-hong-kong-shanghai/1/410461.html
ECOR eliminates Opiates “Vagal nerve stimulation might have the potential for treating Chronic Regional Pain Syndrome through the cholinergic anti-inflammatory pathway.”
https://scholar.google.com/scholar?start=30&q=vagal+stimulation+and+pain+control+&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DPEmb99Jmi4gJ CRPS is associated with a high rate of Opiate abuse https://scholar.google.com/scholar?as_ylo=2016&q=CRPS+And+opiate+abuse&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DcAWkacJs6P0J , So vagal stimulus is an alternative to opiates.
FUJIFILM Avigan Excluded from Trials in Egypt -“ the Egyptian Health Ministry has excluded Japan’s Favipiravir drug sold under the brand name Avigan from studies. “
http://egypttoday.com/Article/1/89218/Egypt-conducts-research-on-Remdesivir-excluded-Avigan-from-studies-top
New EIGR LAMBDA Trial in Canada -Why would Ontario be starting a new Lambda Trial without positive interim data in this SINGLE BLINDED trial - so Stanford researchers know that this 28 day follow up Trial is working and are sharing this fact with their colleagues in Canada. Dr Feld - Principal Investigator in Canada trained at the NIH and Hopkins.
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Open-label, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Jordan Feld, Principal Investigator
University Health Network
Researchers will evaluate the drug peginterferon-lambda (PegIFN-) in ambulatory and hospitalized patients with mild to moderate COVID-19. Peginterferon-lambda has already been used to treat other viral diseases, such as hepatitis B and C. This research will shed light on whether it improves the ability of individuals to clear the virus that causes COVID-19.
https://news.ontario.ca/opo/en/2020/07/ontario-announces-next-round-of-research-projects-to-fight-covid-19.html
Yes ECOR Moves- I bought it 2 weeks ago at $0.81 - nice move. The next catalyst that will move it is the pricing info for EUA dosing (GILD is now charging $3500 a course of Remdesivir under EUA) then I expect a broadening of the EUA to include ARDS- which is why I added at $1.60. I now own more than most institutional owners as I read more and more on the use of transcutaneous vagal stimulation to fight inflammation. COVID studies are being initiated as well -
"Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)"
Sponsor:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Collaborator:
ElectroCore INC
Information provided by (Responsible Party):
Tariq Cheema, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care (active) vs. standard of care alone (SoC), the control group. The gammaCore® (nVNS) treatments will be used acutely and prophylactically. The active and control groups will be diseased and severity matched.
The primary objective is to reduce initiation of mechanical ventilation in patients with CoViD-19 compared to the control group. Secondary objectives are to evaluate cytokine trends/prevent cytokine storms, evaluate supplemental oxygen requirements, decrease mortality of CoViD-19 patients and to delay the onset of mechanical ventilation.
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, Randomized, Controlled
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)
Actual Study Start Date : May 8, 2020
Estimated Primary Completion Date : September 1, 2020
ECOR works in GI Tract -Open-label pilot study: Non-invasive vagal nerve stimulation improves symptoms and gastric emptying in patients with idiopathic gastroparesis
in Neurogastroenterology and Motility 32(7):e13769 · December 2019
... In a proof-of-concept study, noninvasive VNS was shown to decrease GSCI in 35% of Gp subjects using stimulator 3 times a day for greater than 3 weeks [80]. In an open-label study of idiopathic Gp subjects, noninvasive VNS for 4 weeks was associated with improvement of GSCI and gastric emptying
"Short-term non-invasive vagal nerve stimulation led to improved cardinal symptoms and accelerated gastric emptying in a subset of patients with idiopathic gastroparesis. Responders had more severe gastric delay at baseline and clinical improvement correlated with duration of therapy, but not with improvements in gastric emptying."
ECOR explained: Recent Findings- Vagus Nerve: The Key Integrator of Anti-inflammatory Reflex
“Understanding of these components of vagal anti-inflammatory reflex pathways has therapeutic implications, since they could be targeted in various means to stimulate anti-inflammatory regulation in TNFa- related diseases such as inflammatory bowel disease and rheumatoid arthritis. The vagal nerve stimulation, either as an invasive or non- invasive procedure, is becoming increasingly the objective of many researches to evaluate the potential effectiveness of vagus nerve stimula- tion (VNS) to alleviate chronic inflammation. As such VNS has recently been attempted in the management of many clinical disorders:
The recent discovery that cholinergic neurons inhibit acute inflammation has facilitated our understanding of how the ANS moderates immune responses. Recent studies have identified a basic neural pathway that reflexively monitors and inhibits inflammatory response. Therefore, the activation of anti-inflammatory responses has collectively been termed as anti-inflammatory reflex. Inflammatory stimuli activate sensory pathways that relay information to the hypothalamus, which integrates and mobilizes defences to eliminate the inflammation.”
View at ijcep.phcog.interactivedns.com
If not Friday - Monday
ECOR -After Hours Treatment Pricing Release? Like Last Friday.
Hi Tim -Please tweet this Link to support ECOR rise-
https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15481
Cholinergic COVID Treatment- ECOR
https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15481
ECOR Cholinergic Nervous system stimulus -opposes All Bad COVID Inflammation - Sympathetic Nervous system - if more understood - would close at all time high today. https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15481
COVID Rx- ECOR Vagal stimulation Anti-Sympathetic “ In our opinion, sympathetic overactivation could represent a so far undervalued mechanism for a vicious circle between COVID-19 and comorbidities.”
https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15481
ECOR Gammacore the perfect rechargeable COViD therapy Recharges -add doses- with a Refill card ECOR sends.
https://www.gammacore.com/wp-content/themes/gammacore-p2/pdf/gammacore-IFU.pdf
ECOR Pricing 50 & 150 dose machines based on Asthma plus ARDS - 1st off label then On with 2nd EUA - see previous posts.
Tim I just added ECOR at 1.59 -1.60
ARDS next ECOR EUA
“The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience”
https://scholar.google.com/scholar?as_ylo=2020&q=vagal+stimulations+And+ARDS&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DihzkH8WjC2IJ
ECOR Works for ARDS next EUA “Dear Doctor, My name is Dr. Patrick Nemechek,(Internal Medicine, UCLA) and I would like to thank you and your colleagues for your tremendous efforts towards helping those …
Patrick Nemechek MD
Five minutes of VNS is a very potent reducer of systemic pro-inflammatory cytokine levels and results in reduced joint pain in humans with rheumatoid arthritis as well as reduced mortality from septic shock in animals when exposed to intravenous LPS (a gram-negative bacteria molecule), polymicrobial challenge and septic peritonitis. 4, 5, 6, 7
I strongly believe that 5 minutes of tVNS administered 1-3 times per day has the potential to improve the clinical course of COVID-19 in hospitalized patients and may also prevent the deterioration” https://scholar.google.com/scholar?as_ylo=2020&q=vagal+stimulations+And+ARDS&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3D50iXJealpKIJ
NO COMPARISON - HGEN over CYDY - Lenz hits Cytokine chain way earlier than Leron - reduces GM-CSF, TNF/a, IL- 6,etc, AND Th-1- CYDY ONLY Th1 via CCR5. Please- no comparison-5 day discharge in severe- critical COVID Pneumonia.
EIGR Antiviral Anti ARDS Mechanism of Action -Derek Lowe : “Compared to influenza A virus infection in the same ferret model, the coronavirus transcriptional response was much less dramatic, but very distinctive. The team was even able to check transcription in human lung tissue (2 post-mortem samples compared to 2 different healthy patients). That’s a very small sample, necessarily, but it showed a very similar profile: no interferon upregulation and plenty of cytokine transcription. They were able to check circulating levels of these in a larger number of patients (24 infected cases versus 24 uninfected controls), and these results were also consistent: they tested negative for interferon, but showed elevation of CXCL9 (which attracts T cells) and CXCL16 (which attracts NK cells), CCL8 and CCL2 (recruiting monocytes and/or macrophages), and CXCL8 (which attracts neutrophils). A sudden oversupply of these cell types might be behind the pathology of the disease, which could be characterized, if these hypotheses are correct, as a uniquely imbalanced response: far too little interferon and far too many cytokines, too early.
I expect we’ll see quite a few other papers in this area; we’ll see if this picture holds up. But it certainly seems consistent with what people have been seeing in the clinic, and it bodes well for the therapies that are aiming to dampen the cytokine response pathways. Does this mean that administration of IFN-I or IFN-III would also be beneficial?”
https://blogs.sciencemag.org/pipeline/archives/2020/05/21/there-may-be-a-unique-coronavirus-immune-response
EIGR for COVID ARDS -“We conclude that IFN ? constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID -19 such as pneumonia and acute respiratory distress syndrome (ARDS )”
https://www.embopress.org/doi/full/10.15252/emmm.202012465P
HGEN Ready for FDA EUA ramping up manufacturing ability:
SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)--Catalent and Humanigen, Inc. (HGEN) (“Humanigen”) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.
“If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics’ deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.”
BGBIO BRRGF Sharply Up on a Red day
I agree - I don’t think it will be long before HGEN hears from the FDA and is granted an EUA- I also agree with others here that an interim read on P3 is coming soon - remember the P3 population is not as sick as Comp Use.
ALT Vaccine still “in mice”- Moderna outshines in Humans https://www.google.com/amp/s/www.wbrc.com/2020/07/13/altimmune-covid-vaccine-candidate-tested-uab-shows-positive-results/%3foutputType=amp